



Genetics-inspired Therapeutics for Pulmonary Hypertension

A PVRI Symposium

2 June 2026

Royal College of Physicians, London



Due to unforeseen circumstances, we have made an update to the programme. We apologise for any inconvenience. The most up-to-date version is shown below.

Programme

08:00 - 09:00 **Registration and refreshments**

09:00 - 09:05 **Welcome**
Brad Maron, University of Maryland

Genetic insights into pulmonary vascular disease

Chairs: Stefan Graf, University of Cambridge and Micheala Aldred, Indiana University

09:05 - 09:35 **Overview of genetics in PH & hereditary haemorrhagic telangiectasia**
Richard Trembath, King's College London

09:35 - 09:50 **Genetics of the right ventricle**
Lars Harbaum, Universitätsklinikum Hamburg-Eppendorf

09.50 - 10.05 **Q&A**

Therapeutic agents targeting TGF-b/BMP pathway: Part 1

Chairs: Brad Maron, University of Maryland & Luke Howard, Imperial College Healthcare NHS Trust

10:05 - 10:25 **Overview of TGFb-BMP pathway**
Marie-Jose Goumans, Leiden University

10:25 - 10:45 **Biology behind the PAH – HHT overlap**
Wei Li, University Of Cambridge

10:45 - 11:15 **Refreshment break**

11:15 - 11:35 **Sotatercept - a case study**
Luke Howard, Imperial College Healthcare NHS Trust

11:35 - 11:55 **Sotatercept – overview of clinical experience**
Ardeschir Ghofrani, Justus-Liebig-Universität Gießen

11:55 - 12:15 **Sotatercept – deep phenotyping the cardiac response**
Khodr Tello, Justus-Liebig-Universität Gießen

12:15 - 12:30 **Discussion**

12:30 - 13:30

Buffet lunch

Therapeutic agents targeting TGF- β /BMP pathway: Part 2

Chairs: Jane Leopold, Harvard University and Nick Morrell, University of Cambridge

13:30 - 13:50

Sotatercept – what can we learn from the biological response

Paul Yu, Mass General Brigham

13:50 - 14:10

Inhibiting BMP9

Kevin Hart, Pfizer

14:10 - 14:30

LTP001 study

Alex Rothman, The University of Sheffield and Ana-Maria Tanase, Novartis

14:30 - 14:50

Alk1:BMPRII agonism via bispecific clustering antibody for the treatment of HHT & PAH

Patrick Andre, Diagonal Therapeutics

14:50 - 15:10

Modulating TGF- β signalling for pulmonary hypertension and HHT

Nick Morrell, Interact Bio

15:10 - 15:30

Q & A

Developing therapeutic agents to target other genetically validated pathways

Chairs: Brad Maron, University of Maryland and Mark Toshner, University of Cambridge

16:00 - 16:15

Targeting ZIP12

Rachel Gurrell, Apollo Therapeutics

16:15 - 16:30

Sox17

Chris Rhodes, Imperial College London

16:30 - 17:00

Discussion: What information should we be collecting from clinical trials to better inform drug development in this space?

17:00 - 18:30

Networking reception
